Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers

By Matt Fair · September 17, 2014, 6:09 PM EDT

Reckitt Benckiser Group PLC's move to discontinue Suboxone tablets, in lieu of a new dissolving-film version of the opiate addiction treatment, presented no antitrust injury for classes of purchasers who claim...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login